Last reviewed · How we verify

SOFIE — Portfolio Competitive Intelligence Brief

SOFIE pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
[18F]FAPI-74 PET/CT [18F]FAPI-74 PET/CT phase 3 PET imaging agent Fibroblast activation protein (FAP) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ABX advanced biochemical compounds GmbH · 1 shared drug class
  2. Central Hospital, Nancy, France · 1 shared drug class
  3. Centre hospitalier de l'Université de Montréal (CHUM) · 1 shared drug class
  4. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 shared drug class
  5. Institute for Neurodegenerative Disorders · 1 shared drug class
  6. OHSU Knight Cancer Institute · 1 shared drug class
  7. Piramal Imaging Limited · 1 shared drug class
  8. Universidad Central del Caribe · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for SOFIE:

Cite this brief

Drug Landscape (2026). SOFIE — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sofie. Accessed 2026-05-15.

Related